Skip to content

Study on the effectiveness and safety of "Xuanfei Jiejing Zhike Fang" in treating cough after respiratory virus infection

Study on the effectiveness and safety of "Xuanfei Jiejing Zhike Fang" in treating cough after respiratory virus infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081693
Enrollment
Unknown
Registered
2024-03-08
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cough after respiratory virus infection

Interventions

Observer group:Traditional Chinese medicine of "Xuanfei Jiejing Zhike Fang"[Medication composition: 10g perilla leaves, 10g peucedanum, 10g platycodon grandiflorus, 10g aster, 5g fritillaria (crushed)
Control group:Oral Compound Methoxyphenamine Capsules 2 times a day [Manufacturer: Changxing Pharmaceutical Co. Ltd. National Pharmaceutical Approval No. H20020393 Ingredients: Each capsule contains 1

Sponsors

Wangjing Hospital of the Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Meets the post infection diagnostic criteria, with a course of less than 8 weeks; ? History of respiratory virus infection; ? Respiratory virus antigen/nucleic acid has turned negative; ? Age range from 18 to 75 years old, regardless of gender.

Exclusion criteria

Exclusion criteria: ? Suffering from chronic respiratory diseases such as bronchial asthma (including cough variant asthma), chronic bronchitis, chronic obstructive pulmonary disease, bronchiectasis, lung tumors, pulmonary tuberculosis, etc; Other causes of cough (upper airway cough syndrome, gastroesophageal reflux cough, eosinophilic bronchitis, allergic cough, angiotensin converting enzyme inhibitor related cough, etc.); ? Pregnant and lactating women; ? Individuals with severe primary instability of heart, liver, kidney function, and hematopoietic system in combination; ? Mental illness patients; ? Individuals who are allergic to the treatment drugs specified in the plan; ? Individuals who have participated or are currently participating in other clinical trials within the past month; ? Those who are unwilling to accept research measures or cannot cooperate for other reasons.

Design outcomes

Primary

MeasureTime frame
cough evaluation test;

Secondary

MeasureTime frame
Exhaled nitric oxide;Traditional Chinese Medicine Symptom Score;Leicester cough questionnaire;

Countries

China

Contacts

Public ContactGao Feng

Wangjing Hospital of the Chinese Academy of Traditional Chinese Medicine

wjyyhxk@163.com+86 84739045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026